Advanced Malignancies - Healing Genes

Advanced Malignancies

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies

Phase 2


Doctors at the University of California at Los Angeles (UCLA ), seek patients with severe advanced cancers that test positive for NY-ESO-1 antigen to trial a therapeutic gene therapy and vaccine combination. This therapy utilizes the patient’s own (autologous) stem cells, drawn from bone marrow and blood, which will be gene-modified in the lab to impart a gene for the NY-ESO-1 immune receptor, which will then recognize the cancer cells. After chemotherapy to reduce the existing immune system, these modified cells are re-infused to replace the immune system with new cells that have been taught to attack and kill the cancer cells and thereby improve immune system anti-tumor function.. Additionally, a vaccine made from NY-ESO proteins will be provided to mobilize the immune system against the tumor cells.

Follow up assesses the tumor’s response for 90 days and up to 6 years, and includes blood samples and PET scans at 40 days.


  • Be 16 years of age or older
  • Have Stage IV or locally advanced cancers for which no alternative therapies with proven survival advantage are available
  • Life expectancy of > 3 months


  1. Screening to confirm acceptance to the study.
  2. Leukapheresis to collect the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period) to target cancer cells.
  3. Admission to the study center and a course of chemotherapy.
  4. Infusion of the gene-modified stem cells, followed by aldesleukin to promote their growth. This period may last up to 14 days.
  5. Vaccine administration to prompt anti-NY-ESO immune response.
  6. Follow up to assess clinical response for 90 days and up to 6 years, and includes blood samples and PET scans at 40 days.
  7. After day 90, 3 additional doses of vaccine may be given.

Trials will take place at the University of California at Los Angeles (UCLA). Map.
Arun Singh  |  310-829-5471  |  [email protected]
Jonsson Comprehensive Cancer Center
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader